DOVONEX

LOE Approaching

calcipotriene

NDATOPICALSOLUTION
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

CLINICAL PHARMACOLOGY In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D 3 (cholecalciferol) in the skin. Calcipotriene is a synthetic analog of vitamin D 3 . Clinical studies with…

Clinical Trials (4)

NCT01582932Phase 1Completed

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

Started Apr 2013
36 enrolled
Psoriasis
NCT01563068Phase 1Completed

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

Started Apr 2012
18 enrolled
Psoriasis
NCT01139580Phase 3Completed

The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis

Started May 2010
363 enrolled
Psoriasis
NCT00608777Phase 4Terminated

Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

Started Jan 2008
6 enrolled
Plaque Psoriasis